恩威医药
(301331)
| 流通市值：23.67亿 | | | 总市值：23.74亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 338,150,190.03 | 377,012,987.57 | 298,091,486.96 | 362,305,968.24 |
| 结算备付金 | - | - | - | 0 |
| 拆出资金 | - | - | - | 0 |
| 交易性金融资产 | 142,937,212.21 | 97,804,665.07 | 176,716,955.49 | 171,277,142.79 |
| 衍生金融资产 | - | - | - | 0 |
| 应收票据及应收账款 | 125,846,483.71 | 125,605,911.13 | 131,229,600.71 | 141,871,416.46 |
| 其中：应收票据 | - | - | - | 0 |
| 应收账款 | 125,846,483.71 | 125,605,911.13 | 131,229,600.71 | 141,871,416.46 |
| 应收款项融资 | 90,514,854.94 | 93,035,415.1 | 151,763,500.27 | 167,846,557.85 |
| 预付款项 | 29,834,493.19 | 27,489,832.92 | 29,051,233.45 | 27,311,267.25 |
| 应收保费 | - | - | - | 0 |
| 应收分保账款 | - | - | - | 0 |
| 应收分保合同准备金 | - | - | - | 0 |
| 其他应收款合计 | 4,121,566.37 | 4,286,505.57 | 4,323,610.2 | 3,058,987.73 |
| 其中:应收利息 | - | - | - | 0 |
| 应收股利 | - | - | - | 0 |
| 买入返售金融资产 | - | - | - | 0 |
| 存货 | 125,791,700.52 | 130,638,371.09 | 128,282,021.85 | 101,103,589.94 |
| 合同资产 | - | - | - | 0 |
| 一年内到期的非流动资产 | - | - | - | 0 |
| 其他流动资产 | 393,409.53 | 594,866.4 | 562,304.99 | 687,916.2 |
| 流动资产合计 | 857,589,910.5 | 856,468,554.85 | 920,020,713.92 | 975,462,846.46 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | - | - | 0 |
| 债权投资 | - | - | - | 0 |
| 其他债权投资 | - | - | - | 0 |
| 长期应收款 | - | - | - | 0 |
| 长期股权投资 | - | - | - | 0 |
| 其他权益工具投资 | 28,000,000 | 28,000,000 | 20,000,000 | 20,000,000 |
| 其他非流动金融资产 | - | - | - | 0 |
| 投资性房地产 | 24,281,518.25 | 24,880,754.3 | 25,479,990.35 | 26,079,226.4 |
| 固定资产 | 202,237,415.93 | 200,186,431.49 | 200,672,772.07 | 196,924,881.98 |
| 在建工程 | 64,300,032.06 | 66,458,450.91 | 69,726,027.52 | 64,464,534.86 |
| 生产性生物资产 | - | - | - | 0 |
| 油气资产 | - | - | - | 0 |
| 使用权资产 | 2,808,087.28 | 3,271,580.02 | 3,122,835.61 | 3,510,122.65 |
| 无形资产 | 105,387,866.46 | 109,323,926.07 | 113,259,985.68 | 117,282,725.49 |
| 开发支出 | - | - | - | 0 |
| 商誉 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 |
| 长期待摊费用 | 10,894,320.23 | 11,716,258.48 | 12,827,949.2 | 13,451,190.6 |
| 递延所得税资产 | 4,055,510.93 | 4,328,858.59 | 3,908,209.22 | 3,887,423.89 |
| 其他非流动资产 | 37,486,767.02 | 32,481,276 | 29,313,500 | 29,047,000 |
| 非流动资产合计 | 580,004,129.03 | 581,200,146.73 | 578,863,880.52 | 575,199,716.74 |
| 资产总计 | 1,437,594,039.53 | 1,437,668,701.58 | 1,498,884,594.44 | 1,550,662,563.2 |
| 流动负债: | | | | |
| 短期借款 | - | - | - | 0 |
| 向中央银行借款 | - | - | - | 0 |
| 拆入资金 | - | - | - | 0 |
| 交易性金融负债 | - | - | - | 0 |
| 衍生金融负债 | - | - | - | 0 |
| 应付票据及应付账款 | 28,856,475.65 | 48,021,512.4 | 51,050,112.6 | 56,482,167.82 |
| 其中：应付票据 | - | - | - | 0 |
| 应付账款 | 28,856,475.65 | 48,021,512.4 | 51,050,112.6 | 56,482,167.82 |
| 预收款项 | - | - | - | 0 |
| 合同负债 | 27,436,765.99 | 21,896,525.33 | 24,485,734.83 | 19,729,882.4 |
| 应付手续费及佣金 | - | - | - | 0 |
| 应付职工薪酬 | 22,831,281.36 | 23,001,685.03 | 26,725,481.53 | 29,383,273.5 |
| 应交税费 | 9,707,239.08 | 6,370,802.51 | 5,252,827.53 | 17,927,997.62 |
| 其他应付款合计 | 92,638,446.97 | 89,426,529.15 | 92,592,125.71 | 142,305,667.97 |
| 其中:应付利息 | - | - | - | 0 |
| 应付股利 | 0 | - | 0 | 35,642,796.35 |
| 应付分保账款 | - | - | - | 0 |
| 保险合同准备金 | - | - | - | 0 |
| 一年内到期的非流动负债 | 11,958,047.41 | 11,875,649.3 | 186,968,951.22 | 186,595,849 |
| 其他流动负债 | 3,566,779.58 | 2,846,548.29 | 3,183,145.53 | 2,564,884.72 |
| 流动负债合计 | 196,995,036.04 | 203,439,252.01 | 390,258,378.95 | 454,989,723.03 |
| 非流动负债: | | | | |
| 长期借款 | 190,000,000 | 190,000,000 | - | 0 |
| 应付债券 | - | - | - | 0 |
| 优先股 | - | - | - | 0 |
| 永续债 | - | - | - | 0 |
| 租赁负债 | 763,787.97 | 917,028.05 | 933,975.1 | 1,444,953.46 |
| 长期应付款 | - | - | - | 0 |
| 长期应付职工薪酬 | - | - | - | 0 |
| 预计负债 | - | - | - | 0 |
| 递延收益 | 6,910,763.45 | 7,466,668.52 | 8,022,573.59 | 8,785,617.29 |
| 递延所得税负债 | 13,751,468.57 | 13,975,544.42 | 13,456,991 | 12,636,144.68 |
| 其他非流动负债 | - | - | - | 0 |
| 非流动负债合计 | 211,426,019.99 | 212,359,240.99 | 22,413,539.69 | 22,866,715.43 |
| 负债合计 | 408,421,056.03 | 415,798,493 | 412,671,918.64 | 477,856,438.46 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 102,891,887 | 102,891,887 | 102,891,887 | 102,891,887 |
| 其他权益工具 | - | - | - | 0 |
| 优先股 | - | - | - | 0 |
| 永续债 | - | - | - | 0 |
| 资本公积 | 632,903,928.18 | 632,002,109.44 | 631,860,803.47 | 630,958,984.73 |
| 减:库存股 | 33,124,715.17 | 33,124,715.17 | 34,398,230.18 | 34,398,230.18 |
| 其他综合收益 | - | - | - | 0 |
| 专项储备 | - | - | - | 0 |
| 盈余公积 | 51,445,943.5 | 51,445,943.5 | 51,445,943.5 | 51,445,943.5 |
| 一般风险准备 | - | - | - | 0 |
| 未分配利润 | 275,055,939.99 | 268,654,983.81 | 334,412,272.01 | 321,907,539.69 |
| 归属于母公司股东权益合计 | 1,029,172,983.5 | 1,021,870,208.58 | 1,086,212,675.8 | 1,072,806,124.74 |
| 少数股东权益 | - | - | - | 0 |
| 股东权益合计 | 1,029,172,983.5 | 1,021,870,208.58 | 1,086,212,675.8 | 1,072,806,124.74 |
| 负债和股东权益合计 | 1,437,594,039.53 | 1,437,668,701.58 | 1,498,884,594.44 | 1,550,662,563.2 |
| 公告日期 | 2026-10-26 | 2026-08-27 | 2026-04-27 | 2026-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |